TRANSTHERA-B(02617) reaches a project cooperation agreement with Neurocrine.

TRANSTHERA-B(02617) announced that Neurocrine Biosciences, Inc. (NASDAQ: NBIX)(Neurocrine) has entered into a patent transfer and research collaboration agreement with the company to develop NLRP3 inhibitors for the treatment of various diseases. Under the agreement, Neurocrine has been granted exclusive rights to develop, manufacture, and commercialize NLRP3 inhibitors in the Greater China region, while the company retains the rights to develop, manufacture, and commercialize NLRP3 inhibitors in Greater China (Mainland China, Hong Kong, Taiwan, Macau). According to the agreement, the company will receive upfront payments and may receive further milestone payments related to research and sales milestones based on Neurocrine's development and commercialization progress, with a total potential value of the agreement being $881.5 million. The agreement also includes research collaboration between the parties to further develop NLRP3-related technologies.